Updates in Urothelial Carcinoma

New data further support adjuvant chemo in upper tract urothelial cancer after nephroureterectomy, but some experts say that overall survival data are still needed.

Scot Niglio, MD, discusses how urothelial carcinoma treatment has changed, given the FDA’s approval of “a ton of drugs all at once that really work.”

Robert Dreicer, MD, and Robert A. Figlin, MD, discuss “paradigm-shifting” data in bladder cancer that mean optimistic outcomes are “not as much of a fairytale.”

Recent changes to frontline standards for treating advanced urothelial carcinoma have led to new questions about optimal second-line strategies.

Enfortumab vedotin with pembrolizumab improves survival across prespecified subgroups in advanced urothelial carcinoma, irrespective of cisplatin eligibility.

The FDA fully approved erdafitinib for adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 mutation after disease progression.

Nearly one in four patients with locally advanced or metastatic urothelial carcinoma did not get first-line standard-of-care treatment, according to new data.

The FDA approved the combination of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial cancer.

Bladder cancer data presented at ESMO 2023 were met with cheers, with a discussant calling results “monumental” and declaring a new “best first-line” option.

A phase 2 study testing chemo plus immunotherapy showed the approach may allow patients with MIBC to avoid radical cystectomy. But some experts express caution.

Perioperative durvalumab was associated with good event-free survival in patients with muscle-invasive urothelial carcinoma, new phase 2 data show.

The accelerated approval of enfortumab vedotin plus pembrolizumab adds a new option for care for certain urothelial carcinomas. However, some questions persist.